Source: Mediterranee Infection

Abstract

Background.

SARS-CoV-2 infection can cause significant mortality among dependant elderly residents living within medical retirements homes. Objectives. To report the results of SARS-CoV-2 PCR-based screening campaigns conducted in dependent elderly resident in retirement homes in Marseille, France and the follow-up of positive cases.

Methods.

Data of 1690 elderly residents and 992 member staffs were retrospectively collected through interview of the medical team of 23 retirement homes and electronic health recording system of the hospital.

Results.

Elderly residents were predominantly female (64.8%) with a mean age of 83 years old. SARS-CoV-2 detection in residents (226, 13.4%) was significantly higher than in staff members (87, 8.8%), with p=4.10-4 . Of 226 infected residents, 37 (16.4%) were detected on a case-by-case basis because of COVID-19 symptoms and 189 (83.6%) were detected through mass screening; 84.0% had possible COVID-19 symptoms, including respiratory symptoms and signs (48.5%) and fever (47.2%); 118 (52.2%) patients received a course of oral hydroxychloroquine and azithromycin (HCQ-AZ) for at least 3 days; and 47 (20.8%) died. In multivariate, death rate was positively associated with being male (31.5% vs. 13.4%, OR=4.33, p<10-4 ) and being older than 85 years (26.1% vs. 15.7%, OR=3.01, p=0.005) and negatively associated with being diagnosed through mass screening (16.9%, vs. 40.5%, OR=0.20, p<10-4 ) and receiving HCQ-AZ treatment for at least 3 days (14.4% vs. 27.8%, OR=0.41, p=0.017).

Conclusion.

Our data shows that early diagnosis and care of COVID-19 patients at retirement homes can be effective in saving lives.





Related:

61 studies (37 peer reviewed) Early treatment studies are very positive – COVID deaths: 621, 206

China Study of 2882 patients: Beneficial effects exerted by hydroxychloroquine in treating COVID-19 patients via protecting multiple organs

The effect of 5-day course of hydroxychloroquine and azithromycin combination on QT interval in non-ICU COVID19(+) patients

Share on facebook
Share on twitter
Share on whatsapp
On Trend

Latest Stories

American Hero: Ralph C. Lorigo Fights for Client Rights Including Access to Ivermectin for COVID-19 Patients At Risk

Lorigo shared with TrialSite that once doctors learn of all of the studies around the world, and start doing their own homework, they become more open-minded, factoring in the risk-reward analysis. Especially if elderly high risk patients present advanced COVID-19, Lorigo has personally seen the drug potentially contribute to saving the lives of clients. Interestingly, the attorney reports that it would appear that hospital administrations are the most recalcitrant to the idea, even if the patients and the ICU doctor are in support.

Read More »

The Chloroquine Wars Part XIV – How to Rig Research: Surgisphere Part I

It was in these very moments in late May when public health officials lost all credibility—a credibility that cannot be restored without major changes taking place. Despite most evidence pointing to a likelihood of HCQ efficacy, they made their call on the back of data supposedly tucked away in a database that nobody had verified, declared it definitive, then swiftly pushed for policy changes around the world.

Read More »

Another New York State Supreme Court Justice Ivermectin Order Helping 81-Year-Old Farmer

Ivermectin, a medicine for parasites, has been around for four decades. While not authorized for use against COVID-19, dozens of studies show materially positive results. At well-established human dosage levels, the drug is safe: hundreds of millions of people are treated with it every year mostly in the tropics for various parasite-borne diseases, such as River Blindness in Nigeria.

Read More »

The Chloroquine Wars Part XIII -A Clockwork Orange Man

Immediately following HCQ’s Trump moment, the media went on an all-out blitz to associate the topic of HCQ with a sense of fear. Fear of Trump, fear of death, fear of incompetence, fear of opposing scientific authorities, fear of using medicine needed by somebody else, and fear of the unknown. And the campaign of fear didn’t stop there.

Read More »